{"organizations": ["ADC Therapeutics"], "uuid": "099f76a89c89b4cc5248267a288d8e77cfd451eb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530677?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "ADC Therapeutics brings in $80mm through second round", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "ADC Therapeutics brings in $80mm through second round", "spam_score": 0.0, "site_type": "news", "published": "2015-09-05T02:40:00.000+03:00", "replies_count": 0, "uuid": "099f76a89c89b4cc5248267a288d8e77cfd451eb"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530677?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "ADC Therapeutics brings in $80mm through second round", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "ADC Therapeutics brings in $80mm through second round Deal Date: Sep-01-2015 / Deal # 201530677 Executive Summary \nThrough what appears to be its second financing round (following a $50mm seed round in 2012 and $20mm investment in 2013, both by Auven Therapeutics Holdings), ADC Therapeutics SARL has now raised $80mm from new European and US investors, Auven, and partner AstraZeneca . Proceeds will fund lead candidate ADCT301, in Phase I for lymphoma and leukemia, and will also support development of up to two antibody-drug conjugates under the company's partnership with AZ's MedImmune division. ADC plans to have seven candidates in clinical trials by mid-2017.", "external_links": [], "published": "2015-09-05T02:40:00.000+03:00", "crawled": "2015-09-05T18:15:21.355+03:00", "highlightTitle": ""}